Aminoacidopathies: Prevalence, Etiology, Screening, and Treatment Options
- 1.9k Downloads
Inborn errors of metabolism (IEMs) are a group of inherited metabolic disorders which are caused by mutations in the specific genes that lead to impaired proteins or enzymes production. Different metabolic pathways are perturbed due to the deficiency or lack of enzymes. To date, more than 500 IEMs have been reported with most of them being untreatable. However, fortunately 91 such disorders are potentially treatable, if diagnosed at an earlier stage of life. IEMs have been classified into different categories and one class of IEMs, characterized by the physiological disturbances of amino acids is called as aminoacidopathies. Out of 91 treatable IEM, thirteen disorders are amino acid related. Aminoacidopathies can be detected by chromatography and mass spectrometry based analytical techniques (e.g., HPLC, GC–MS, LC–MS/MS) for amino acid level changes, and through genetic assays (e.g., PCR, TaqMan Genotyping, DNA sequencing) at the mutation level in the corresponding genes. Hence, this review is focused to describe thirteen common aminoacidopathies namely: Phenylketonuria (PKU), Maple Syrup Urine Disease (MSUD), Homocystinuria/Methylene Tetrahydrofolate Reductase (MTHFR) deficiency, Tyrosinemia type II, Citrullinemia type I and type II, Argininosuccinic aciduria, Carbamoyl Phosphate Synthetase I (CPS) deficiency, Argininemia (arginase deficiency), Hyperornithinemia–Hyperammonemia–Homocitrullinuria (HHH) syndrome, N-Acetylglutamate Synthase (NAGS) deficiency, Ornithine Transcarbamylase (OTC) deficiency, and Pyruvate Dehydrogenase (PDH) complex deficiency. Furthermore, the etiology, prevalence and commonly used analytical techniques for screening of aminoacidopathies are briefly described. This information would be helpful to researchers and clinicians especially from developing countries to initiate newborn screening programs for aminoacidopathies.
KeywordsAminoacidopathies Metabolic disorders HPLC LC–MS/MS GC–MS Newborn screening
This review originated as a result of our research project, “Diagnosis of treatable inborn metabolic disorders of intellectual disability” (Project No. CRP/PAK14-02; Contract No. CRP/14/012) funded by the International Centre for Genetic Engineering and Biotechnology (ICGEB), Italy.
FRA conceived the idea and revised/approved the manuscript. MW wrote the draft and revised it several times, HNK provided information on genetics of the diseases, AT and MI wrote and revised the analytical/diagnostic section, and HA provided advice on clinical aspects of the described diseases.
- Carvalho-Silva M, Gomes LM, Scaini G, Rebelo J, Damiani AP, Pereira M, Andrade VM, Gava FF, Valvassori SS, Schuck PF, Ferreira GC, Streck EL (2017) Omega-3 fatty acid supplementation decreases DNA damage in brain of rats subjected to a chemically induced chronic model of Tyrosinemia type II. Metab Brain Dis 32:1043–1050CrossRefPubMedGoogle Scholar
- Castiglioni C, Verrigni D, Okuma C, Diaz A, Alvarez K, Rizza T, Carrozzo R, Bertini E, Miranda M (2015) Pyruvate dehydrogenase deficiency presenting as isolated paroxysmal exercise induced dystonia successfully reversed with thiamine supplementation. Case report and mini-review. Eur J Paediatr Neurol 19(5):497–503CrossRefPubMedGoogle Scholar
- Ciara E, Rokicki D, Halat P, Karkucinska-Wieckowska A, Piekutowska-Abramczuk D, Mayr J, Trubicka J, Szymanska-Debinska T, Pronicki M, Pajdowska M, Dudzinska M, Gizewska M, Krajewska-Walasek M, Ksiazyk J, Sperl W, Ploski R, Pronicka E (2016) Difficulties in recognition of pyruvate dehydrogenase complex deficiency on the basis of clinical and biochemical features. The role of next-generation sequencing. Mol Genet Metab Rep 7:70–76CrossRefPubMedPubMedCentralGoogle Scholar
- Coughlin CR 2nd, van Karnebeek CD, Al-Hertani W, Shuen AY, Jaggumantri S, Jack RM, Gaughan S, Burns C, Mirsky DM, Gallagher RC, Van Hove JL (2015) Triple therapy with pyridoxine, arginine supplementation and dietary lysine restriction in pyridoxine-dependent epilepsy: neurodevelopmental outcome. Mol Genet Metab 116(1–2):35–43CrossRefPubMedGoogle Scholar
- Dobrowolski SF, Heintz C, Miller T, Ellingson C, Ellingson C, Ozer I, Gokcay G, Baykal T, Thony B, Demirkol M, Blau N (2011) Molecular genetics and impact of residual in vitro phenylalanine hydroxylase activity on tetrahydrobiopterin responsiveness in Turkish PKU population. Mol Genet Metab 102(2):116–121CrossRefPubMedGoogle Scholar
- Imtiaz F, Al-Mostafa A, Allam R, Ramzan K, Al-Tassan N, Tahir AI, Al-Numair NS, Al-Hamed MH, Al-Hassnan Z, Al-Owain M, Al-Zaidan H, Al-Amoudi M, Qari A, Balobaid A, Al-Sayed M (2017) Twenty novel mutations in BCKDHA, BCKDHB and DBT genes in a cohort of 52 Saudi Arabian patients with maple syrup urine disease. Mol Genet Metab Rep 11:17–23CrossRefPubMedPubMedCentralGoogle Scholar
- Monroe GR, Frederix GW, Savelberg SM, de Vries TI, Duran KJ, van der Smagt JJ, Terhal PA, van Hasselt PM, Kroes HY, Verhoeven-Duif NM, Nijman IJ, Carbo EC, van Gassen KL, Knoers NV, Hovels AM, van Haelst MM, Visser G, van Haaften G (2016) Effectiveness of whole-exome sequencing and costs of the traditional diagnostic trajectory in children with intellectual disability. Genet Med 50:686–689Google Scholar
- Nagamani SC, Shchelochkov OA, Mullins MA, Carter S, Lanpher BC, Sun Q, Kleppe S, Erez A, O’Brian Smith E, Marini JC, Lee B, Members of the Urea Cycle Disorders (2012b) A randomized controlled trial to evaluate the effects of high-dose versus low-dose of arginine therapy on hepatic function tests in argininosuccinic aciduria. Mol Genet Metab 107(3):315–321CrossRefPubMedPubMedCentralGoogle Scholar
- Pena MJ, Almeida MF, van Dam E, Ahring K, Belanger-Quintana A, Dokoupil K, Gokmen-Ozel H, Lammardo AM, MacDonald A, Robert M, Rocha JC (2015) Special low protein foods for phenylketonuria: availability in Europe and an examination of their nutritional profile. Orphanet J Rare Dis 10:162CrossRefPubMedPubMedCentralGoogle Scholar
- Pena-Quintana L, Scherer G, Curbelo-Estevez ML, Jimenez-Acosta F, Hartmann B, Roche F, Meavilla-Olivas S, Perez-Cerda C, Garcia Segarra N, Giguere Y, Huppke P, Mitchell GA, Monch E, Trump D, Vianey-Saban C, Trimble ER, Vitoria-Minana I, Reyes-Suarez D, Ramirez-Lorenzo T, Tugores A (2017) TYROSINEMIA TYPE II: Mutation update, eleven novel mutations and description of five independent subjects with a novel founder mutation. Clin Genet. https://doi.org/10.1111/cge.13003 PubMedGoogle Scholar
- Perucho J, Gonzalo-Gobernado R, Bazan E, Casarejos MJ, Jimenez-Escrig A, Asensio MJ, Herranz AS (2015) Optimal excitation and emission wavelengths to analyze amino acids and optimize neurotransmitters quantification using precolumn OPA-derivatization by HPLC. Amino Acids 47(5):963–973CrossRefPubMedPubMedCentralGoogle Scholar
- Prinsen HC, Schiebergen-Bronkhorst BG, Roeleveld MW, Jans JJ, Sain-van der Velden MG, Visser G, van Hasselt PM, Verhoeven-Duif NM (2016) Rapid quantification of underivatized amino acids in plasma by hydrophilic interaction liquid chromatography (HILIC) coupled with tandem mass-spectrometry. J Inherit Metab Dis 39(5):651–660CrossRefPubMedPubMedCentralGoogle Scholar
- Qadri SK, Ting TW, Lim JS, Jamuar SS (2016) Milder form of urea cycle defect revisited: report and review of hyperornithinaemia-hyperammonaemia-homocitrullinuria (HHH) syndrome diagnosed in a teenage girl presenting with recurrent encephalopathy. Ann Acad Med Singapore 45(12):563–566PubMedGoogle Scholar
- Yoshitoshi-Uebayashi EY, Toyoda T, Yasuda K, Kotaka M, Nomoto K, Okita K, Yasuchika K, Okamoto S, Takubo N, Nishikubo T, Soga T, Uemoto S, Osafune K (2017) Modelling urea-cycle disorder citrullinemia type 1 with disease-specific iPSCs. Biochem Biophys Res Commun 486(3):613–619CrossRefPubMedGoogle Scholar